Affinity Asset Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Affinity Asset Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150,000	Closed	-$16.1M	–	96
2023 Q1	$16.1M	Buy	150,000 +75,000	+100%	+$8.63M	5.31%	4
2022 Q4	$8.25M	Buy	75,000 +50,000	+200%	+$3.24M	3.24%	7
2022 Q3	$1.48M	Buy	+25,000	New	+$1.14M	0.41%	44

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Affinity Asset Advisors's RXDX Position: Q2 2023 in Review

Affinity Asset Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 150,000 shares — an estimated $16.1M sold.

Affinity Asset Advisors first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $16.1M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Affinity Asset Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Affinity Asset Advisors sold 150,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $16.1M.
Affinity Asset Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Affinity Asset Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $16.1M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.